ResMed onderzoek wijst uit dat CPAP-naleving verbeterd wordt door bewaking op afstand, zelfcontrole in drie landen
- Studie gepresenteerd op de ATS International Conference onderzocht meer dan 4 miljoen PAP-gebruikers in de VS, Brazilië, Mexico en Brazilië
DALLAS-(BUSINESS WIRE)- De controle op afstand en de zelfcontrole van de patiënt kunnen CPAP-naleving voor mensen met slaapapneu verbeteren, blijkt uit onderzoek dat door ResMed (NYSE: RMD) (ASX: RMD) wordt gepresenteerd op de American Thoracic Society’s 2019 ATS International Conference.
De gemiddelde PAP (positieve luchtwegdruk)-naleving, de gouden standaard voor de behandeling van slaapapneu, is ongeveer 50 procent bij het gebruik van verouderde technologie zonder cloud connectiviteit of externe controle mogelijkheden. Volgens de nieuwe studie, vonden de onderzoekers beduidend hogere percentages toen zij patiënten evalueerden die 100% cloud-connectable apparaten gebruikten die controle op afstand mogelijk maken: meer dan 31.000 Brazilianen, 17.000 Mexicanen, en 4,1 miljoen Amerikanen.
ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries
-
- Study presented at ATS International Conference examined more than 4 million PAP users in U.S., Brazil, Mexico
DALLAS–(BUSINESS WIRE)– Remote monitoring and patient self-monitoring can drive CPAP adherence for people with sleep apnea, according to research presented by ResMed (NYSE: RMD) (ASX: RMD) at the American Thoracic Society’s 2019 ATS International Conference.
Average adherence to PAP (positive airway pressure), the gold standard for treating sleep apnea, is approximately 50 percent when using legacy technology with no cloud connectivity or remote monitoring capabilities. According to the new study, researchers found significantly higher rates when they evaluated patients on 100% cloud-connectable devices that enable remote monitoring: more than 31,000 Brazilians, 17,000 Mexicans, and 4.1 million Americans.
| Percent of study | ||||
| participants | ||||
| achieving 90-day | ||||
| PAP adherence (all | Remotely and | |||
| remotely monitored) | self-monitored | |||
| United States | 74% | 85% | ||
| Brazil | 72% | 83% | ||
| Mexico | 66% | 81% | ||
“These results equate a strong endorsement for remote and self-monitoring technology,” said study coauthor and ResMed Chief Medical Officer Carlos M. Nunez, M.D. “Despite different healthcare systems, financial and social issues, patients in all three countries have reached above-average adherence rates when treated with 100% cloud-connectable PAP devices.”
Researchers also urge clinicians to enroll their PAP patients in a self-monitoring program like myAir, ResMed’s patient engagement app. While 26 percent of U.S. patients in this study had registered for myAir, only 8.1 percent of Brazilian patients and 2.8 percent of Mexican patients had.
PAP adherence was defined for this study using the U.S. Centers for Medicare and Medicaid Services definition: using PAP usage of four hours per night for 70 percent of nights in a 30-day span within the first 90 days of therapy.
About ResMed
At ResMed (NYSE: RMD) (ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190521005262/en/
Contacts
For media
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com